|
| 孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效及安全性分析 |
| Clinical efficacy and safety analysis of montelukast sodium in the treatment of cough variant asthma in children |
| 投稿时间：2020-05-26 修订日期：2020-05-26 |
| DOI： |
| 中文关键词: 孟鲁司特钠 布地奈德 小儿咳嗽变异性哮喘 |
| 英文关键词: Montelukast sodium budesonide cough variant asthma in children |
| 基金项目: |
|
| 摘要点击次数: 62 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：观察孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的临床效果及安全性。方法：对于我院2016年12月~2018年10月收治的74例小儿咳嗽变异性哮喘患儿，按照数字表法分为两组，对照组采用布地奈德雾化吸入治疗，研究组采用孟鲁司特钠联合布地奈德治疗。分析两组的治疗效果和不良反应发生情况。结果：研究组治疗有效率为97.3%，高于对照组的83.8%；研究组的不良反应率为5.41%，低于对照组的21.6%。两组疗效和不良反应的差异均有统计学意义（P<0.05）。结论：孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘可有效提升临床效果，且具有较高的安全性。 |
| 英文摘要: |
| Objective: To observe the clinical effect and safety of montelukast sodium combined with budesonide in the treatment of cough variant asthma in children. Methods: 74 children with cough variant asthma treated in our hospital from December 2016 to October 2018 were divided into two groups according to the digital table method, the control group was treated with budesonide inhalation therapy, and the research group was treated with Meng Treatment with rustinate combined with budesonide. The treatment effect and the occurrence of adverse reactions in the two groups were analyzed. Results: The treatment effective rate of the study group was 97.3%, higher than that of the control group of 83.8%; the adverse reaction rate of the study group was 5.41%, lower than that of the control group of 21.6%. The differences in efficacy and adverse reactions between the two groups were statistically significant (P <0.05). Conclusion: Montelukast sodium combined with budesonide in the treatment of pediatric cough variant asthma can effectively improve the clinical effect and has high safety. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
